ANZAR Losartan Potassium 50mg Tablet 100's
RXDRUG-DRP-897-01-100
Discreet Packaging
FDA-registered Products
FDA-licensed Pharmacies
Indications/Uses
Losartan is used in the management of hypertension and may have a role in patients who are unable to tolerate ACE inhibitors. It has also been tried in heart failure and myocardial infarction.
Dosage/Direction for Use
In hypertension, the usual initial dose is 50 mg once daily. The maximum effect is achieved in about 3-6 weeks after initiating treatment. The dose may be increased, if necessary, to 100 mg once daily or in 2 divided doses as directed by the physician.
An initial dose of 25 mg once daily may be used in the elderly ≥75 years, and for patients with moderate to severe hepatic impairment (CrCl 20 mL/min) or intravascular fluid retention. A reduced dose should also be considered for patients with hepatic impairment.
An initial dose of 25 mg once daily may be used in the elderly ≥75 years, and for patients with moderate to severe hepatic impairment (CrCl 20 mL/min) or intravascular fluid retention. A reduced dose should also be considered for patients with hepatic impairment.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Pregnancy & lactation.
Patients who are hypersensitive to any component of this product. Losartan also contraindicated in pregnancy and breastfeeding. If pregnancy is detected, losartan should discontinued immediately.
Warnings
Anzar contains FD&C yellow #5 (tartrazine) which may cause allergic reactions to susceptible persons.
Special Precautions
In patients with renal artery stenosis. Reduced doses may be required in patients with hepatic impairment. Patients with volume depletion, (eg those who have received high-dose diuretic therapy) may experience hypotension, which may be minimized by initiating treatment with a low dose of losartan.
Since hyperkalemia may occur, serum-potassium concentrations should be monitored, especially in the elderly and patients with renal impairment, and the concomitant use of potassium-sparing diuretics should be avoided.
Since hyperkalemia may occur, serum-potassium concentrations should be monitored, especially in the elderly and patients with renal impairment, and the concomitant use of potassium-sparing diuretics should be avoided.
Adverse Reactions
Adverse effects of losartan have been reported to be usually mild and transient, and include dizziness and dose related orthostatic hypotension. Hypotension may occur particularly in patient with volume depletion, (eg those who have received high-dose diuretics).
Impaired renal function and rarely, rash, angioedema and raised alanine aminotranferase may occur. Hyperkalemia and myalgia have been reported. Losartan appears less likely than ACE inhibitors to cause cough.
Impaired renal function and rarely, rash, angioedema and raised alanine aminotranferase may occur. Hyperkalemia and myalgia have been reported. Losartan appears less likely than ACE inhibitors to cause cough.
Drug Interactions
K-sparing diuretics.
Storage
Store at temperatures not exceeding 30°C.
Action
Angiotensin II receptor blocker/antihypertensive.
Pharmacokinetics: Losartan is readily absorbed from the GIT following oral administration with an oral bioavailability of about 33%. It undergoes first-pass metabolism to form an active carboxylic acid metabolite E-3174 (EXP-3174), which has greater pharmacological activity than losartan and some inactive metabolites. Metabolism is primarily by cytochrome P-450 isoenzymes CYP2C9 and CYP3A4. Peak plasma concentrations of losartan and E-3174 occur in about 1 hr and 3-4 hrs, respectively, after an oral dose. Both losartan and E-3174 are >98% bound to plasma proteins. Losartan is excreted in the urine and in the feces via bile, as unchanged drug and metabolites. Following oral dosing, about 35% of the dose is excreted in the urine and about 60% in the feces. The terminal elimination t½ of losartan and E-3174 are about 1.5-2.5 hrs and 3-9 hrs, respectively.
Pharmacokinetics: Losartan is readily absorbed from the GIT following oral administration with an oral bioavailability of about 33%. It undergoes first-pass metabolism to form an active carboxylic acid metabolite E-3174 (EXP-3174), which has greater pharmacological activity than losartan and some inactive metabolites. Metabolism is primarily by cytochrome P-450 isoenzymes CYP2C9 and CYP3A4. Peak plasma concentrations of losartan and E-3174 occur in about 1 hr and 3-4 hrs, respectively, after an oral dose. Both losartan and E-3174 are >98% bound to plasma proteins. Losartan is excreted in the urine and in the feces via bile, as unchanged drug and metabolites. Following oral dosing, about 35% of the dose is excreted in the urine and about 60% in the feces. The terminal elimination t½ of losartan and E-3174 are about 1.5-2.5 hrs and 3-9 hrs, respectively.
MedsGo Class
Angiotensin II Antagonists
Features
Brand
Anzar
Full Details
Dosage Strength
50mg
Drug Ingredients
- Losartan Potassium
Drug Packaging
Tablet 100's
Generic Name
Losartan Potassium
Dosage Form
Tablet
Registration Number
DRP-897-01
Drug Classification
Prescription Drug (RX)
Please sign in so that we can notify you about a reply